## Mark L Gonzalgo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7408547/publications.pdf

Version: 2024-02-01

		471509	3	45221	
59	1,478	17		36	
papers	citations	h-index		g-index	
			_		1
65	65	65		2072	
63	63	63		2072	
all docs	docs citations	times ranked		citing authors	

#	Article	IF	Citations
1	A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative) Tj ETQq1 1	0.784314	rgBT /Overlock
2	Prostatic Ductal Adenocarcinoma Controlled for Tumor Grade, Stage, and Margin Status Does Not Independently Influence the Likelihood of Biochemical Recurrence in Localized Prostate Cancer After Radical Prostatectomy. Archives of Pathology and Laboratory Medicine, 2022, 146, 1012-1017.	2.5	6
3	Single-stage Xi® robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes. Minerva Urology and Nephrology, 2022, 74, .	2.5	16
4	Robotic <i>&gt;vs</i> Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta―Analysis (ROBUUST Collaborative Group). Journal of Endourology, 2022, 36, 752-759.	2.1	22
5	Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence. JAMA Network Open, 2022, 5, e2148329.	5.9	12
6	Prostate cancer upgrading and adverse pathology in Hispanic men undergoing radical prostatectomy. World Journal of Urology, 2022, 40, 2017-2023.	2.2	1
7	Androgen Suppression Therapy Is Associated with Lower Recurrence of Non–muscle-invasive Bladder Cancer. European Urology Focus, 2021, 7, 142-147.	3.1	14
8	Re: The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate. Journal of Urology, 2021, 205, 342-342.	0.4	0
9	Obesity-Dependent Adipokine Chemerin Suppresses Fatty Acid Oxidation to Confer Ferroptosis Resistance. Cancer Discovery, 2021, 11, 2072-2093.	9.4	43
10	Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. Journal of Urology, 2021, 205, 1344-1351.	0.4	5
11	Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers. Prostate, 2021, 81, 866-873.	2.3	3
12	Reply by Authors. Journal of Urology, 2021, 206, 27-28.	0.4	0
13	Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy. Journal of Urology, 2021, 206, 22-28.	0.4	6
14	Impact of Plant-Based Diet on PSA Level: Data From the National Health and Nutrition Examination Survey. Urology, 2021, 156, 205-210.	1.0	10
15	Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). Journal of Urology, 2021, 206, 568-576.	0.4	27
16	Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer: a propensity matched analysis. Minerva Urology and Nephrology, 2021, 73, 572-580.	2.5	7
17	Variance of Tumor Grade at Radical Prostatectomy With Assessment of Each Tumor Nodule Versus Global Grading. Archives of Pathology and Laboratory Medicine, 2021, , .	2.5	1
18	Localized Amyloidosis of the Seminal Tract is not Associated With Subsequent Development of Systemic Amyloidosis. Urology, 2021, , .	1.0	1

#	Article	IF	CITATIONS
19	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. World Journal of Urology, 2020, 38, 1959-1968.	2.2	22
20	Timing of adjuvant chemotherapy and overall survival following radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 75.e15-75.e22.	1.6	9
21	Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma. Urology, 2020, 137, 108-114.	1.0	11
22	Performance of Multiparametric MRI of the Prostate in Biopsy Na $\tilde{A}$ -ve Men: A Meta-analysis of Prospective Studies. Urology, 2020, 146, 189-195.	1.0	9
23	Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort. Journal of Urology, 2020, 203, 505-511.	0.4	63
24	Prospective Evaluation of Focal High Intensity Focused Ultrasound for Localized Prostate Cancer. Journal of Urology, 2020, 204, 483-489.	0.4	18
25	Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy. Journal of Urology, 2020, 204, 450-459.	0.4	26
26	Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy Journal of Clinical Oncology, 2020, 38, TPS3172-TPS3172.	1.6	1
27	Reply by Authors. Journal of Urology, 2020, 203, 511-511.	0.4	0
28	Propensity-matched analysis of stage-specific efficacy of adjuvant chemotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 877-885.	1.6	3
29	Impact of Surgical Technique on Surgical Margin Status Following Partial Cystectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 870-876.	1.6	6
30	Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate. PLoS ONE, 2019, 14, e0211153.	2.5	3
31	Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis. Oncogene, 2019, 38, 838-851.	5.9	19
32	Trends in Utilization of Robotic and Open Partial Nephrectomy for Management of cT1 Renal Masses. European Urology Focus, 2019, 5, 482-487.	3.1	42
33	A comparison of overall survival and perioperative outcomes between partial and radical nephrectomy for cT1b and cT2 renal cell carcinoma—Analysis of a national cancer registry. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 90.e9-90.e14.	1.6	15
34	Malakoplakia of the prostate diagnosed on multiparametric-MRI ultrasound fusion guided biopsy: A case report and review of the literature. Urology Case Reports, 2018, 18, 94-96.	0.3	3
35	Comparison of readmission and short-term mortality rates between different types of urinary diversion in patients undergoing radical cystectomy. World Journal of Urology, 2018, 36, 393-399.	2.2	11
36	Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate. Journal of Biological Chemistry, 2018, 293, 20123-20136.	3.4	12

#	Article	IF	Citations
37	Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet, The, 2018, 391, 2525-2536.	13.7	537
38	Lymph node yield as a predictor of overall survival following inguinal lymphadenectomy for penile cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 471.e19-471.e27.	1.6	20
39	Stress-Induced Low Complexity RNA Activates Physiological Amyloidogenesis. Cell Reports, 2018, 24, 1713-1721.e4.	6.4	63
40	MP06-20 APPLICATION OF AUA RISK STRATIFICATION FOR NON-MUSCLE INVASIVE BLADDER CANCER: LONG-TERM RESULTS IN A CONTEMPORARY SINGLE INSTITUTION COHORT. Journal of Urology, 2018, 199, .	0.4	1
41	Screening for aggressive prostate cancer: A single-center experience using the 4Kscore and multiparametric MRI for the detection of Gleason 7 or higher prostate cancer Journal of Clinical Oncology, 2017, 35, 84-84.	1.6	0
42	What is the current role of partial nephrectomy for T2 tumors?. Canadian Journal of Urology, 2017, 24, 8698-8704.	0.0	4
43	Robotic Partial Nephrectomy with the Da Vinci Xi. Advances in Urology, 2016, 2016, 1-5.	1.3	19
44	Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice. PLoS ONE, 2016, 11, e0148851.	2.5	28
45	Adaptation to Stressors by Systemic Protein Amyloidogenesis. Developmental Cell, 2016, 39, 155-168.	7.0	136
46	Systemic Reprogramming of Translation Efficiencies on Oxygen Stimulus. Cell Reports, 2016, 14, 1293-1300.	6.4	73
47	Current Clinical Applications of Testicular Cancer Biomarkers. Urologic Clinics of North America, 2016, 43, 119-125.	1.8	22
48	Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. Journal of Urology, 2016, 195, 612-618.	0.4	57
49	Cancer detection between peripheral zone and transitional zone targeted biopsies: Preliminary results from a prospective cohort of men undergoing MRI-US fusion biopsy Journal of Clinical Oncology, 2016, 34, 56-56.	1.6	0
50	Comparison of survival outcomes for African American and Caucasian men with advanced penile cancer in Florida Journal of Clinical Oncology, 2016, 34, 490-490.	1.6	0
51	Impact of pelvic lymph node dissection during radical prostatectomy on 30-day post operative complications: Results from a large national database Journal of Clinical Oncology, 2016, 34, 238-238.	1.6	O
52	Perioperative outcomes of open and minimally invasive nephroureterectomy and pre-operative predictors of complications: An analysis using the National Surgical Quality Improvement Program database Journal of Clinical Oncology, 2016, 34, 408-408.	1.6	0
53	Focal Therapy for Prostate Cancer: Don't Believe the Hype. Journal of Urology, 2015, 194, 876-877.	0.4	1
54	Operative technique and early experience for robotic-assisted laparoscopic nephroureterectomy (RALNU) using da Vinci Xi. SpringerPlus, 2015, 4, 298.	1.2	25

#	Article	IF	CITATIONS
55	Alterations in DNA Methylation May Be the Key to Early Detection and Treatment of Schistosomal Bladder Cancer. PLoS Neglected Tropical Diseases, 2015, 9, e0003696.	3.0	15
56	Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise. Indian Journal of Urology, 2015, 31, 273.	0.6	19
57	Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients Journal of Clinical Oncology, 2015, 33, 63-63.	1.6	2
58	A meta-analysis of health-related quality of life after primary treatment for prostate cancer as measured by the Expanded Prostate Cancer Index Composite Journal of Clinical Oncology, 2015, 33, 39-39.	1.6	1
59	Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients Journal of Clinical Oncology, 2015, 33, e16042-e16042.	1.6	0